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50ppp-dsRNA. Weber et al. show that
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incoming influenza A viruses and directly
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subunit PB2-627K are more RIG-I
resistant than those with avian-adapted
PB2-627E.
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The cytoplasmic RNA helicase RIG-I mediates innate
sensing of RNA viruses. The genomes of influenza A
virus (FLUAV) are encapsidated by the nucleoprotein
and associated with RNA polymerase, posing poten-
tial barriers to RIG-I sensing. We show that RIG-I rec-
ognizes the 50-triphosphorylated dsRNA on FLUAV
nucleocapsids but that polymorphisms at position
627 of the viral polymerase subunit PB2 modulate
RIG-I sensing. Compared to mammalian-adapted
PB2-627K, avian FLUAV nucleocapsids possessing
PB2-627E are prone to increased RIG-I recognition,
and RIG-I-deficiency partially restores PB2-627E
virus infection of mammalian cells. Heightened
RIG-I sensing of PB2-627E nucleocapsids correlates
with previously established lower affinity of 627E-
containing PB2 for nucleoprotein and is increased
by further nucleocapsid instability. The effect of
RIG-I on PB2-627E nucleocapsids is independent
of antiviral signaling, suggesting that RIG-I-nucleo-
capsid binding alone can inhibit infection. These
results indicate that RIG-I is a direct avian FLUAV
restriction factor and highlight nucleocapsid disrup-
tion as an antiviral strategy.
INTRODUCTION
Influenza A viruses (FLUAV; family Orthomyxoviridae) are a sig-
nificant health threat. Regular, global outbreaks are occurring
due to replenishment from a seemingly unlimited reservoir of
strains in birds (Cauldwell et al., 2014; Klenk, 2014; Ma¨nz
et al., 2013). FLUAV virions consist of a lipid envelope with
the glycoproteins HA and NA, which also provide the basis forCell Hotaxonomic classification, as well as the proton channel M2.
The inner leaflet of the viral envelope is covered by the M1 pro-
tein. Inside the particles are eight nucleocapsids containing the
negative-strand RNA genome encapsidated by the nucleopro-
tein (NP) and associated with the RNA polymerase complex
with subunits PB1, PB2, and PA. The eight genome segments
encode the main structural proteins, auxiliary proteins (NS1
and NEP) and sometimes other, strain-dependent, factors.
Gene expression is regulated by partially complementary 50
and 30 end sequences (the ‘‘panhandle’’) that pseudocircularize
the single-stranded RNA genome and serve as promoter for
transcription and replication. An outstanding feature of FLUAV
is that most parts of the replication cycle occur in the nucleus.
Retinoic acid-inducible gene I (RIG-I) is an RNA helicase that
acts as a major host sensor for virus infections in the cytoplasm
(Yoo et al., 2014). RIG-I recognizes nonself RNA structures
and activates a signaling cascade leading to phosphorylation
of transcription factor IRF3 and induction of the antiviral type I
interferons (IFN-a/b).
RIG-I contains a central multipartite helicase/ATPase domain
flanked by N-terminal caspase recruitment domains (CARDs)
and a C-terminal domain (CTD) (Yoo et al., 2014). Unstimulated
RIG-I is in an autorepressed, monomeric conformation with the
CARDs confined and the CTD exposed. When the CTD binds a
ligand RNA, RIG-I undergoes a conformational switch, enabling
it to expose the CARDs for interaction with TRIM25 andMAVS to
initiate antiviral signaling (Gack, 2014; Kowalinski et al., 2011;
Rawling and Pyle, 2014).
Synthetic short 50ppp-dsRNA represents the optimal RIG-I
ligand (Schlee et al., 2009; Schmidt et al., 2009), a structure
with remarkable similarity to the panhandle formed by the
annealed 50 and 30 genome ends of segmented negative-strand
RNA viruses (Schlee, 2013; Weber and Weber, 2014b). Accord-
ingly, naked genomic RNA of FLUAV and other negative-strand
RNA viruses is an excellent activator of RIG-I (Habjan et al.,
2008; Hornung et al., 2006; Pichlmair et al., 2006).We recently re-
ported that RIG-I is capable of recognizing 50ppp-dsRNAst & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevier Inc. 309
Figure 1. Activation of RIG-I Signaling by
Incoming Influenza Virus Nucleocapsids
(A and B) RIG-I activity assays. A549 cells were
preincubated for 1 hr with inhibitors, inoculated
with strain A/PR/8/34 (moi 1), or left uninfected
(mock) for 1 hr at 4C, incubated 1 hr at 37C, and
analyzed. (A) Oligomerization assay. Lysates of
cells treated with CHX (50 mg/ml), LMB (16 nM),
ActD (1 mg/ml), or IVM (50 mM) were separated by
native PAGE and immunostained for RIG-I. Actin
served as loading control. (B) Conformational
switch. Lysates as in (A) were subjected to limited
trypsin digest and analyzed by RIG-I immunoblot.
The Ponceau S protein stain (representative
section shown) serves as loading control for the
digested samples.
(C) Quantification of total FLUAV segment 7 RNA
by RT-qPCR. Input represents RNA amounts
harvested after the 1 hr inoculation period at 4C.
(D) IRF3 activation. A549 cells were pretreated with
inhibitors, inoculated with strain A/PR/8/34 (moi 1),
or left uninfected (mock) for 1 hr at 4C, and incu-
bated for 1 hr under inhibitor treatment. Lysates
from cells were separated by native PAGE and
analyzed by immunoblotting for phosphorylated
IRF3 (P-IRF3) and actin as described (Weber et al.,
2013). See also Figures S1A–S1C.panhandles also in the physiological context, when packaged by
viral NP and polymerase into nucleocapsids (Weber et al., 2013).
That study, however, had focused on the cytoplasmically
replicating bunyaviruses. Therefore, it remained open whether
the panhandles of FLUAV nucleocapsids could also be sensed
by the cytoplasmic RIG-I, and whether this occurs during the
passage of the incoming nucleocapsids from the endosome
to the nucleus early in infection. Here, we report that the transiting
FLUAV nucleocapsids are indeed recognized and directly
impaired by RIG-I, and that the degree of RIG-I sensitivity varies
depending on adaptivemutations in the polymerase subunit PB2.310 Cell Host & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevier Inc.RESULTS
Activation of RIG-I by Incoming
FLUAV Nucleocapsids
At the onset of infection, the nucleocap-
sids of FLUAV are released from endo-
somes to be transported through the
cytoplasm and into the nucleus. Only
there do they start primary transcription,
followed by translation and genome repli-
cation. To investigate the interaction be-
tween incoming nucleocapsids (and not
their RNA products arising later on) and
RIG-I in the cytoplasm, we (1) synchro-
nized infection by incubating the virus
inoculum at 4C for 1 hr, (2) allowed the
subsequent infection at 37C to proceed
for only 1 hr, and (3) added various inhib-
itors to ensure restriction to the immediate
early infection phase. The inhibitors were
cycloheximide (CHX; blocks protein syn-thesis and therefore viral genome replication), leptomycin B
(LMB; inhibits nuclear export of nucleocapsids), and actinomycin
D (ActD; inhibits viral transcription) (see Figure S1A available on-
line). In addition, we tested ivermectin (IVM), which is known to
block the nuclear import machinery (Wagstaff et al., 2012).
Human A549 cells were pretreated with one or several of the
inhibitors and 1 hr infected with strain A/PR8/34 (H1N1) at a mul-
tiplicity of infection (moi) of 1 as outlined above. Irrespective of
the inhibitor, incoming FLUAV nucleocapsids triggered two
markers of RIG-I activation: the formation of homo-oligomers
(Figure 1A), and the conformational switch reflected by a partial
Figure 2. RIG-I Interacts with Incoming Influenza Virus Nucleocapsids and Is Activated in a 50ppp-dsRNA-Dependent Manner
(A–C) CHX / LMB-treated A549 cells were infected with A/PR/8/34 (moi 1) for 1 hr. (A) Cells analyzed for RIG-I and FLUAV by 3D GSD superresolution immu-
nofluorescence microscopy. Scale bar, 1 mm. Insets are digitally magnified and shown below the main image (taken from one individual cell). (B) Coimmuno-
precipitation. Cell lysates were subjected to immunoprecipitation (IP) using antibodies against p21 (negative control), RIG-I, or FLUAV NP and analyzed by
immunoblot. Input control is 2% of the lysate. Asterisks (*) indicate unspecific bands. (C) Cosedimentation assay. Cell lysates were separated by a discontinuous
CsCl gradient (2% lysate as input control) and fractions analyzed by immunoblotting.
(D) Conditions for activation of RIG-I by nucleocapsids in vitro. Dialyzed lysate of RIG-I-expressing S2 cells was mixed with nucleocapsids of strain A/PR/8/34
(RNPs) or a control preparation (CTRL) and supplemented with 1mMATP. The nucleocapsids had either been pretreated with 5 mg RNase A (A), 1 U RNase III (III),
or 2 U shrimp alkaline phosphatase (SAP) or left untreated () for 1 hr at 37C. RIG-I conformational switch was assayed after 1 hr of nucleocapsid coincubation at
37C. See also Figures S2A–S2K.trypsin resistance (Figure 1B). RIG-I activation by incoming
nucleocapsids was comparable to levels obtained by 1 hr trans-
fection of naked virus particle RNA (vRNA). Quantification by
RT-qPCR demonstrated the expected absence of viral RNA
synthesis (Figures 1C and S1B). In line with this, transcription in-
hibition by various NTP-depleting agents also had no influence
on RIG-I activation by FLUAV (Figure S1C). Nonetheless, not
only RIG-I but also its downstream target IRF3 was activated
by the incoming nucleocapsids (Figure 1D). It must be remarked
that in all our experiments, virus stocks were used which were
free of defective interfering particles (data not shown), a known
activator of RIG-I (Baum et al., 2010). Moreover, in agreement
with a previous study (Killip et al., 2014), we noted that addition
of ActD to themix containing CHX and LMB results in occasional
background activation of antiviral signaling in uninfected cells
(data not shown). We therefore conducted the majority of sub-
sequent experiments with CHX/LMB treatment and within the
short, 1 hr period of synchronized infection, conditions that
were optimal for robustly studying interactions of RIG-I with
incoming nucleocapsids.
RIG-I Binds to the Panhandle on FLUAV Nucleocapsids
Confocal microscopy revealed that the incoming nucleocapsids
are colocalizing with RIG-I, but not with the related helicase
MDA5 (Figure S2A; data not shown). Superresolution micro-Cell Hoscopy suggests that RIG-I directly attaches on one side of the
rod-like nucleocapsids (Figure 2A). The stability of these cocom-
plexes was tested by pull-down experiments. Although the viral
input was barely detectable, as expected for a 1 hr infection, the
RIG-I immunoprecipitates contained enriched amounts of NP
(Figure 2B), indicating interaction of RIG-I with incoming nucleo-
capsids. Again, this was not dependent on viral RNA synthesis
(Figure S2B). When cell lysates were separated in a CsCl
gradient, we observed a partial, virus-induced shift of RIG-I
from higher-density fractions toward the lower-density fractions
which also contained the nucleocapsids (Figure 2C; fractions 7,
8, and 9 in uninfected cells versus fractions 3, 4, and 6 in infected
cells). RIG-I was also activated and shifted toward lower-density
CsCl fractions when its ATPase activity was inhibited with
ADPCAlF3, suggesting that complex formation is independent
of downstream events (Figures S2C–S2E). We also used our
insect cell/in vitro system (Weber et al., 2013). Extracts of
Drosophila S2 cells expressing human RIG-I were dialyzed and
supplemented with ATP (to support RIG-I activation). The re-
combinant RIG-I reacted to purified and dialyzed FLUAV nucle-
ocapsids by conformational switching, oligomerization, and a
shift of RIG-I fractions in the CsCl gradient (Figures S2F–S2H).
To test the structural determinants of RIG-I activation, purified
FLUAV nucleocapsids were pretreated in vitro with enzymes.
Both destruction of dsRNA by RNase III and cleavage of thest & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevier Inc. 311
Figure 3. Adaptive Mutations in PB2 Influ-
ence the Activation of RIG-I by FLUAV
Nucleocapsids
(A) RIG-I activation by viruses with different PB2-
627 signatures. Cells were infected with strains
of A/quail/Shantou/2061/00 (H9N2), A/Thai/KAN-
1/04 (H5N1), A/Hamburg/05/2009 (pH1N1), or
A/WSN/33 (H1N1) containing avian-signature E
or mammalian-signature K at PB2-627. Infections,
CHX/LMB treatment, and RIG-I conformational
switch testing were performed as described for
Figures 1 and 2.
(B) Quantification of virus RNAs by RT-qPCR
for genomic segment 7. Input represents RNA
amounts harvested after the 1 hr infection period.
(C) Cosedimentation assay. Lysates of cells
infected with PB2 variants of A/WSN/33 (H1N1)
using our standard 1 hr protocol were separated by
a CsCl gradient and analyzed by immunoblotting.
(D) RIG-I-dependent IFN induction by incoming
nucleocapsids. A549 cells were transfected with
the indicated siRNAs or a negative control siRNA
(CTRL). A549 cells siRNA depleted of RIG-I or
MDA5 were pretreated with CHX and LMB, and
infected with FLUAV strains (moi 1) for 16 hr. IFN-b
mRNA levels were determined by real-time RT-
PCR. Mean and SDs from three independent ex-
periments are shown. See also Figures S3A–S3H.50ppp by a phosphatase aborted RIG-I stimulation, whereas
the ssRNA-specific RNase A had no such effect (Figure 2D).
Importantly, RIG-I activation did not depend on the specific
nucleocapsid preparation method, and was also observed for
nucleocapsids that were affinity purified via a strep-tagged
PB2 subunit (Figures S2I–S2K). Also, cotransfection experi-
ments demonstrated that the pull-down of NP by RIG-I is
dependent on the genomic RNA, and not on protein-protein in-
teractions (see below). Together, these data suggest that RIG-I
directly interacts with the 50ppp dsRNA panhandle on intact
FLUAV nucleocapsids and in a manner that is independent of
mammalian cofactors or viral RNA synthesis.
PB2 Is a RIG-I Antagonist
Avian FLUAV strains need to acquire adaptive mutations to
establish infection in mammals. A major determinant of host312 Cell Host & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevier Inc.switching and virulence is the polymerase
subunit PB2 (Hatta et al., 2001). PB2 posi-
tion 627, in particular, carries in avian
strains a glutamic acid (E), but in most
mammalian-adapted strains a lysine (K)
(Subbarao et al., 1993). The reason for
themammalian selection pressure toward
PB2-627K is not fully understood (Cauld-
well et al., 2014; Ma¨nz et al., 2013). Inter-
estingly, however, chickens are known to
be deficient in RIG-I (Barber et al., 2010).
Using the conformational switch assay,
we investigated whether RIG-I might
be involved in the mammalian-specific
effects on avian-signature PB2 polymer-ases. Human A549 cells were exposed to the immediate early
infection phase of variants of four FLUAV strains, A/quail/
Shantou/2061/00 (H9N2), A/Thai/KAN-1/04 (H5N1), pandemic
A/Hamburg/05/2009 (pH1N1), or A/WSN/33 (H1N1). In all cases,
those viruses with the avian signature PB2-627E activated RIG-I
much more strongly than those with the mammalian signature
PB2-627K (Figures 3A and S3A). These differences were
not due to variations in input RNA or RNA synthesis, as viral
RNA levels were comparable and did not increase during the
1 hr experiment (Figures 3B and S3B–S3D). Also in CsCl gradient
assays, we observed a more pronounced shift of RIG-I fractions
in response to a PB2-627E virus (Figure 3C, left panels). The
PB2-627E virus also relocalized the RIG-I interactors MAVS
and TRIM25 (Figure 3C, right panels), further supporting the
notion of a stronger RIG-I activation by the avian-signature
nucleocapsids.
Figure 4. RIG-I Evasion by PB2-E627K
(A) Activity of A/WSN/33-based minireplicon sys-
tems containing PB2-627K, -627E, or no PB2 () in
HEK293 WT, DRIG-I, or DMDA5 cells.
(B) Reporter activities in HEK293 cells producing
VLPs containing nucleocapsids with the indicated
PB2 signatures.
(C) Reporter activities in WT and deletion cells in-
fected with VLPs. Cells had been pretransfected
with PB1, PA, NP, and matching PB2.
(D) Multicycle virus kinetics. 293WT orDRIG-I cells
were infected with the indicated PB2 variants of
strain A/Thai/KAN-1/04 (H5N1) at anmoi of 0.0001.
Virus yields were determined 24 hr later by plaque
assay. In all cases, mean and SDs from three in-
dependent experiments are shown.
(E) Single-cycle virus kinetics. Cells were infected
at an moi of 1 and monitored for NP expression
over time. See also Figures S4A–S4D.The A/PR/8/34 strain used for the initial RIG-I activation exper-
iments (see Figures 1 and 2) contains PB2-627K (Foeglein et al.,
2011). A comparison of A/PR/8/34 with PB2-627K and 627E
variants of A/WSN/33 (H1N1) demonstrates its relatively weak
RIG-I activation potential (Figure S3E), thus being in line with
the correlation between reduced RIG-I activation and the PB2-
627K signature. Virus-like particles containing a A/WSN/33
(H1N1) reporter minigenome (VLPs) showed the same PB2-
627-dependent phenotype, independent of the particular enve-
lope protein (Figure S3F). This confirms that nucleocapsids
are the critical component. As expected, RIG-I activation by
PB2-627E virus was independent of any viral RNA synthesis
(Figure S3G). We also measured IFN induction obtained afterCell Host & Microbe 17, 309–31overnight infection by the different FLUAV
strains, again under CHX and LMB.
Surprisingly, despite the clear effects on
RIG-I activation described above, there
were no consistent PB2-627-dependent
differences in IFN induction, both in WT
and in RIG-I- depleted knockdown cells
(Figures 3D and S3H). Of note, human-
adapted PB2-627K has a higher polymer-
ase activity in mammalian cells (Naffakh
et al., 2000) but nonetheless activated
RIG-I much more weakly than PB2-
627E. This again argues against RNA syn-
thesis as a trigger of RIG-I. Collectively,
our data indicate that the adaptive
mutation PB2-E627K represents a viral
countermechanism to RIG-I recognition,
even if it has no significant effect on IFN
induction.
RIG-I Influences Infection by
Incoming PB2-627E Nucleocapsids
PB2-627E confers reduced polymerase
activity in mammalian cells, whereas
in avian cells the activity is similar to
PB2-627K (Massin et al., 2001; Patersonet al., 2014). The species-specific differences were attributed
to a mammalian restriction factor acting on PB2-627E only
(Mehle and Doudna, 2008). We wondered whether RIG-I could
be contributing to PB2-627E suppression in mammalian cells.
The classic assay for measuring FLUAV polymerase activity
is the minireplicon reporter system, consisting of plasmid-
expressed polymerase subunits and NP that encapsidate,
transcribe, and replicate a reporter minigenome bearing
panhandle sequences. Minireplicon activity in human 293 WT
cells confirmed the difference between the two PB2 variants
(Figure 4A). We generated knockout 293 cells (Figure S4A) to
test the effect of RIG-I on minireplicon activity but could not
detect major differences to WT cells or MDA5 knockout cells9, March 11, 2015 ª2015 Elsevier Inc. 313
(see Figure 4A). It needs to be noted, however, that here the re-
combinant nucleocapsids are not entering the cytoplasm as in
infection, but are artificially assembled in the nucleus by the
plasmid-encoded proteins. Thus, as an alternative closer to the
immediate-early infection situation, we employed VLPs contain-
ing recombinant FLUAV nucleocapsids. Reporter activity in the
293 WT cells used to produce VLPs for strain A/WSN/33
(H1N1) differed between the two PB2 variants, as expected
(Figures 4B and S4B). However, VLPs with PB2-627E regained
considerable activity upon infection of DRIG-I cells, but not in
WT cells or DMDA5 cells (Figure 4C). Curiously, in cells that
lacked the RIG-I adaptor MAVS, PB2-627E could also not be
rescued, suggesting that signaling may not be necessary (see
below). We also tested the influence of RIG-I on viral multiplica-
tion. To obtain multicycle growth, we infected 293 WT or DRIG-I
cells for 24 hr with moi 0.0001 of PB2 variants of strain A/Thai/
KAN-1/04 (H5N1). The absence of RIG-I rescued the low yields
of the PB2-627E virus by one order of magnitude, whereas the
PB2-627K virus was slightly reduced (Figure 4D). Overall, the
approximately 50,000-fold growth difference between the PB2
signature viruses in WT cells decreased to 400-fold in DRIG-I
cells. Since RIG-I is activated by nucleocapsid entry, we also
monitored the initial establishment of infection. WT or DRIG-I
cells were infected with moi 1, and the synthesis of NP was
assayed for 8 hr. For PB2-627K viruses, NP was detected from
4 hr p.i. on in both cell types (Figures 4E, S4C, and S4D). For
the PB2-627E virus, by contrast, NP was detected at 8 hr p.i.
in WT cells, but from 6 hr on in DRIG-I cells. Since viral entry is
affected neither by the PB2 signature nor by the cell genotype
(Figure S4E), we conclude that RIG-I targets PB2-627E-type
nucleocapsids during the onset of infection.
Species- and Signaling-Independent Antiviral Effect
of RIG-I
An unexpected result of our VLP infection experiments (see Fig-
ure 4C) was that the attenuated phenotype of incoming PB2-
627E nucleocapsids was not rescued by deleting the signaling
adaptorMAVS. Similarly, also virus with PB2-627E was delayed
in DMAVS cells (Figure 5A). To investigate this further, we
transcomplemented DRIG-I cells with an ATPase-negative
RIG-I mutant (K270A) that is unable to signal but still able to
bind RNA (Takahasi et al., 2008). Strikingly, the RIG-I K270A
mutant was as potent as WT RIG-I in delaying the onset of
PB2-627E virus and VLP infection (Figures 5B and S5). This is
in line with our observation that chemical ATPase inhibition of
RIG-I does not impede activation and nucleocapsid binding
(see Figures S2C–S2E). Transcomplementation with human
RIG-I also endowed chicken cells with the ability to slow down
PB2-627E virus infection (Figure 5C). Again, this was indepen-
dent of antiviral signaling. These data suggest that the binding
of RIG-I to incoming nucleocapsids (see Figures 2 and S2) is
sufficient to delay infection by FLUAV strains with the avian
PB2-627E signature. Thus, RIG-I signaling may not be required
for the restriction of avian strains early in infection.
Nucleocapsid Stability Influences RIG-I Binding
and Sensitivity
The 627K adaptation is known to increase the binding of PB2
to NP (Labadie et al., 2007). Although this had been disputed314 Cell Host & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevieas an artifact of the stronger polymerase activity (and hence
nucleocapsid formation) by PB2-627K (Cauldwell et al., 2013),
others had shown stronger NP binding by PB2-627K also in a
nucleocapsid-free in vitro system (Ng et al., 2012). In our imme-
diate-early infection setup, infection occurred for 1 hr, and the
formation of daughter nucleocapsids was impossible due to
CHX treatment. Nonetheless, also under these conditions NP
coprecipitated more PB2-627K than PB2-627E, confirming the
adaptation-specific differences in binding affinity (Figure 6A).
Moreover, NP/PB2-627E interactions slightly increased in
DRIG-I cells that were infected (see Figure 6A) or are harboring
minireplicon systems (Figures S6A and S6B).
RIG-I directly interacts with the panhandles of FLUAV nucleo-
capsids (see Figures 2D and S2K). Interestingly, RIG-I pulled
down more incoming nucleocapsids of the PB2-627E type
than of the PB2-627K type (Figure 6B). Moreover, the PB2 pro-
tein of the 627K type was found to be coprecipitated, but not
PB2 of the 627E type. Similar results were obtained with recom-
binant nucleocapids of the minireplicon system, an experimental
setup that also allowed us to demonstrate that RIG-I-NP interac-
tions depend on the encapsidated genome RNA (Figure 6C).
Thus, nucleocapsids of the PB2-627E type are more efficiently
bound by RIG-I.
The lower affinity of PB2-627E to NP may enable RIG-I to
better access the nucleocapsid-borne panhandle RNA. This
would implicate that the strength of the polymerase-nucleo-
capsid interaction influences RIG-I activity. To directly test
this hypothesis, we disrupted the polymerase complex with a
PB1-derived peptide (PB1-T6Y) (Wunderlich et al., 2011). The
inhibitor peptide massively increased RIG-I activation by
incoming nucleocapsids, and independently of the PB2-627
signature (Figures 6D and S6C). Thus, the strength of poly-
merase binding, modulated either naturally (by PB2 mutation)
or artificially (by disrupting PB1-PA interactions), sensitizes
nucleocapsids to RIG-I.
In summary, our results indicate that FLUAV nucleocapsids
are prone to signaling-independent RIG-I inhibition during their
passage through the cytoplasm early in infection. RIG-I recog-
nizes the panhandle structure on the viral genome RNA, which
is normally bound by the polymerase complex. The sensitivity
to RIG-I is determined by the well-known host adaptation at
PB2-627, which affects the binding affinity of PB2 to nucleocap-
sids. Thus, RIG-I apparently represents one of the mammalian
restriction factors driving adaption of avian FLUAV strains to-
ward tighter polymerase binding.
DISCUSSION
An outstanding feature of influenza viruses is the replication in
the nucleus. This allows access to the cellular transcription and
splicing machineries, and—as our results suggest—the hiding
from cytoplasmic RIG-I during most phases of the infection cy-
cle. In fact, since orthomyxoviruses are also unique with respect
to the unusually high number of genome segments (and hence
RIG-I ligands), it is possible that moving into the nucleus initially
evolved as a RIG-I counterstrategy. In line with this, efficient
interaction with the nuclear import machinery was shown to be
a determinant of host adaptation (Gabriel et al., 2011; Hudjetz
and Gabriel, 2012; Resa-Infante et al., 2008). However, the virusr Inc.
Figure 5. Signaling-Independent RIG-I Ef-
fect on Early Infection
Single-cycle infection kinetics of A/WSN/33 on
human cells lacking MAVS (A) or RIG-I (B), or on
chicken DF-1 cells that naturally lack RIG-I (C). The
DRIG-I and the DF-1 cells were transiently trans-
fected with plasmids encoding GFP (negative
control), FLAG-RIG-I WT, or FLAG-RIG-I K270A, as
indicated. Overexpression was controlled using
antibodies against GFP or the N-terminal Flag tag
of the RIG-I constructs. See also Figure S5.remains vulnerable during the transit to the nucleus, since at
this stage of infection neither the classic IFN antagonist NS1
(Hale, 2014) nor the host response suppressors PA-X (Jagger
et al., 2012) or PB1-F2 (Varga et al., 2011) would be expressed.
Therefore, it appears plausible that the nucleocapsids them-Cell Host & Microbe 17, 309–31selves have to cope with the pathogen
recognition system, an assumption that
is in agreement with our data and also
with previous reports that FLUAV poly-
merase subunits can prevent IFN induc-
tion (Marcus et al., 2005; Pe´rez-Cidoncha
et al., 2014) and interact with RIG-I and
MAVS (Graef et al., 2010; Iwai et al.,
2010; Li et al., 2014; Liedmann et al.,
2014). Moreover, for influenza B virus it
was demonstrated that nucleocapsids
were sufficient to induce IFN, whereas
for FLUAV RNA synthesis was required
(O¨sterlund et al., 2012). These com-
parative data again point toward nucleo-
capsids being able to both induce and
suppress innate immunity, dependent on
the genetic background.
The connection between RIG-I activa-
tion and IFN induction is not straightfor-
ward. Avian FLUAV strains that strongly
activated RIG-I were in fact IFN inducers
weaker than or equal to the mammalian
strains whose nucleocapsids had in-
hibited RIG-I. Most likely, the underlying
reason is found in the differences in RNA
polymerase activities, which are insepa-
rable from the RIG-I inhibition capacity.
While PB2-627E nucleocapsids have low
RNA synthesis rates but are strong activa-
tors of RIG-I, PB2-627K nucleocapsids
have a highly active polymerase but inhibit
RIG-I. Thus, the RIG-I inhibition by PB2-
627Kmight be overwhelmed by the higher
RNA synthesis rate.
It was previously stated that IFN induc-
tion by FLUAV occurs exclusively through
RNA synthesis products (Killip et al., 2014;
O¨sterlund et al., 2012). However, we
observed IRF3 activation by incoming
nucleocapsids even when viral transcrip-tion was shut off by ActD treatment. This appears to contradict
the results by Killip et al., who had not seen any such IRF3
activation (Killip et al., 2014). However, in that study IRF3 was
assayed at 8 hr postinfection, a time point at which IRF3 activity
may have waned, as IRF3 returns to the inactive state in case of9, March 11, 2015 ª2015 Elsevier Inc. 315
Figure 6. Effect of the PB2 627 Signature on
Protein-Protein Interactions
(A) NP immunoprecipitation. Cells were CHX/LMB
treated and infected with A/WSN/33 strains
carrying PB2-627K or 627E as described for 1A.
Lysates were immunoprecipitated 1 hr later
with anti-NP and immunoblotted as indicated.
Normalized quantifications of the immunopre-
cipitated proteins are shown below. Note that
amounts of viral input proteins are too low to be
detected in the total extracts.
(B) RIG-I immunoprecipitations from infected cells.
HEK293 cells were infected with A/WSN/33
PB2 variants as described for Figure 1A. Im-
munoprecipations with anti-RIG-I and immuno-
blottingwere performed as indicated for Figure 2B.
(C) RIG-I immunoprecipitations of recombinant
nucleocapsids. HEK293 cells were transfected
with A/WSN/33 NP combined with GFP or the
PB2 variants (left panel), or with all A/WSN/
33 minireplicon plasmids (right panel). Immuno-
precipations with anti-RIG-I were performed as
indicated in (B).
(D) Polymerase destabilization. A549 cells were
infected with PB2 variants of strain A/WSN/33
(moi 1), treated with peptides Borna-X-Tat (CTRL)
or PB11-15 T6Y-Tat (PB1-T6Y), and tested for RIG-I
conformational switch 1 hr postinfection. See also
Figures S6A–S6C.low inducers (Long et al., 2014). We therefore propose that
incoming FLUAV nucleocapsids can activate RIG-I and antiviral
signaling, similar to those of influenza B virus (O¨sterlund et al.,
2012) and the cytoplasmic RNA viruses (Weber et al., 2013).
IFN induction by nucleocapsids is, however, comparatively
weak, and the subsequent RNA synthesis becomes the domi-
nant IFN elicitor once the nucleocapsids have reached the
nucleus.
Although PB2-627K had no apparent bearing on IFN induc-
tion, for PB2-627E viruses and VLPs the establishment of
infection was slowed down by RIG-I. Strikingly, while deletion
of RIG-I accelerated infection by avian strains, deletion of the
downstream adaptorMAVS did not. Moreover, a signaling-inac-
tive mutant of RIG-I was as potent as WT RIG-I itself in slowing
down PB2-627E viruses. It is therefore likely that the binding
of RIG-I to the panhandle RNA results in a direct (although
transient) antiviral effect against avian strains. The mammalian-
adapted nucleocapsids are more efficient in hiding their
panhandle, and it could be speculated that this is due to the
stronger binding of the PB2 to the NP. The signaling-indepen-
dent antiviral effect may also explain why RIG-I follows the
nucleocapsids into the nucleus at the late stage of infection
(Li et al., 2014).
Besides PB2-627K, there might be more factors influencing
the RIG-I sensitivity of nucleocapsids. The circulating 2009
pandemic pH1N1 strains have retained the PB2-627E signature
but acquired compensating second-site mutations (Mehle and
Doudna, 2009; Yamada et al., 2010). Nonetheless, our direct
comparisons between variants of four FLUAV strains that316 Cell Host & Microbe 17, 309–319, March 11, 2015 ª2015 Elseviediffered only in position PB2-627 strongly indicate that this major
adaptation is in fact a RIG-I escape mechanism. It will be
interesting to see whether other adaptive mutations in the poly-
merase or the NP also affect RIG-I.
FLUAV epidemics feed from avian reservoirs. Wild bird spe-
cies, e.g., ducks, express functional RIG-I, but domestic chicken
do not (Barber et al., 2010; Kowalinski et al., 2011). Many avian
FLUAV strains cause asymptomatic infection, e.g., in ducks,
but an acute systemic disease in chicken (Kim et al., 2009). Pop-
ulations of wild birds are comparatively disperse, i.e., overt
disease would reduce the chance of viral spread. Chickens, by
contrast, are held under crowded conditions and with a con-
stant, nonnatural replenishment of susceptible individuals. A
certain RIG-I sensitivity may allow FLUAV to persist in the wild
bird reservoir. In domestic chickens, there is no selection pres-
sure on sparing the host, and the absence of RIG-I could enable
rapid viral spread. In humans, the viral transmission mode
requires replication to levels causing respiratory symptoms.
Hence, it could be speculated that mutations suppressing RIG-
I activation are needed for efficient and sustainable infection of
humans, but not in chicken (no RIG-I) or wild birds (RIG-I enables
asymptomatic infection). While RIG-I appears to be acting on
incoming nucleocapsids of avian-adapted viruses, other host
cell factors are likely to contribute to the PB2-directed host
restriction during later stages of infection.
Applying a polymerase-disrupting peptide massively in-
creased RIG-I activation by nucleocapsids. This uncovers the
full potential of RIG-I and implies that even for avian-adapted
strains only a fraction of the nucleocapsids is actuallyr Inc.
recognized. Therefore, drugs targeting the FLUAV polymerase
complex will have the secondary benefit of boosting antiviral
host responses.
In sum, our data indicate that incoming FLUAV nucleocapsids
are prone to a direct antiviral inhibition by RIG-I, and that
the degree of RIG-I sensitivity is dependent on nucleocapsid
stability.
EXPERIMENTAL PROCEDURES
Cells and Viruses
A549, HEK293, DF-1, MDCK II, and Drosophila S2 cells were cultivated as
described (Weber et al., 2013). FLUAV A/PR/8/34, the recombinant strains
of A/quail/Shantou/2061/2000 (H9N2) (Baron et al., 2013), A/Hamburg/
05/2009 (pH1N1), A/WSN/33 (H1N1), and A/WSN/33 with Strep-tagged
PB2 (Rameix-Welti et al., 2009) were grown on MDCK II cells. A/Thai/KAN-
1/04 (H5N1) was grown on chicken DF-1 cells (Manz et al., 2012). All viruses
were entirely sequenced and confirmed to harbor only the intended
mutations.
Infections
Cells were washed once with phosphate-buffered saline (PBS) and inoculated
for 1 hr at 4Cwith virus dissolved in OptiMEM (Invitrogen) or 250 ml cell super-
natant containing VLPs. The inoculum was replaced with DMEM containing
0.2% BSA and (except for VSV-G VLP infections) 1 mg/ml L-1-tosylamido-2-
phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich), and
cells were further incubated at 37C.
RIG-I Activation Assays
Analyses of RIG-I conformation and oligomerization were described elsewhere
(Weber et al., 2013; Weber and Weber, 2014a). For cosedimentation assays
from mammalian cells, cell lysates were prepared as for coimmunoprecipita-
tion (see below). The cleared lysates were loaded on a discontinuous 5%–
15% CsCl gradient in 20 mM Tris/HCl (pH 7.9), 200 mM NaCl, and centrifuged
at 52,000 rpm for 2 hr at 12C in a SW60 rotor (Beckman). Altogether 12 frac-
tions were recovered from top to bottom and pelleted at 45,000 rpm for 1 hr at
4C in a TLA45 rotor (Beckman). Pellets were dissolved in sample buffer,
boiled for 5 min, and analyzed by immunoblotting. Proteins were detected
with rabbit polyclonal anti-A/quail/Shantou/2061/00 (H9N2) (Baron et al.,
2013) at 1:8,000 and the mouse monoclonals anti-RIG-I ALME-1 (Enzo Life
Sciences; 1:1,000), anti-MAVS (Abcam; 1:500), and anti-human TRIM25
(BD Transduction Laboratories, 1:5,000).
Cosedimentation assays with S2 cell samples were performed by a similar
procedure. Briefly, 50 ml dialyzed lysates (containing 100 mg protein) were
mixed with 50 ml of dialyzed PR/8/34 nucleocapsids and supplemented with
1mMATP. After 1 hr at 37C the samples were analyzed using a discontinuous
10%–30% CsCl gradient.
Inhibitor Treatments
CHX, CuSO4, ActD, and IVM were purchased from Sigma Aldrich and LMB
from Biomol. Cells were pretreated with CHX (50 mg/ml, stocks dissolved
in DMSO), LMB (16 nM, stocks dissolved in ethanol), ActD (1mg/ml, stocks
dissolved in DMSO), or IVM (50 mM, stocks dissolved in DMSO) for 1 hr
before infection. Inhibitors were also included in the virus inoculum, and the
incubation medium. ADPCAlF3 treatment was performed as described
(Weber et al., 2013).
Immunofluorescence Microscopy
For superresolution immunfluorescence by ground state depletion (GSD)
microscopy, samples were prepared as described for confocal microscopy
(see Supplemental Information) with minor modifications. As secondary anti-
bodies, donkey anti-rabbit Alexa Fluor 555 (FLUAV) and goat anti-mouse
Alexa Fluor 647 (RIG-I) were used, and samples were embedded in 50 mM
Tris-HCl (pH 8.0) dissolved in 10% Vectashield mounting medium
(VectorLabs) and 90% glycerol. Analysis was performed with the Leica SR
GSD microscope.Cell HoPurification of Native Viral Nucleocapsids
MDCK II cells were seeded in nine T175 cell culture flasks at a confluency of
40% and infected with FLUAV strain PR/8/34 at an moi of 0.01 or left unin-
fected (control). Supernatants were harvested at 48 hr p.i., and nucleocapsids
were purified as described (Weber et al., 2013).
Coimmunoprecipitation Assay
Immunoprecipitations using mouse monoclonals anti-p21 (Santa Cruz
Biotechnology) and anti-RIG-I (ALME-1) were performed as described
(Weber et al., 2013). Mouse monoclonal anti-NP (HB65) (Wisskirchen et al.,
2011) was used at a 1:200 dilution in RIPA buffer. Mouse monoclonals
anti-p21 (1:500), anti-RIG-I ALME-1 (1:1,000), and rabbit polyclonal H9N2
(1:8,000) were used for immunoblotting.
Enzymatic Treatment of Nucleocapsids
Dialyzed nucleocapsids were treated with RNase A, RNase III, or SAP and
incubated with dialyzed lysates fromRIG-I-expressing S2 cells (supplemented
with 1 mM ATP) as described (Weber et al., 2013).
Real-Time RT-PCR
RNA was isolated from cells using the RNeasy Mini Kit (QIAGEN), and 10 ng
was analyzed with the one-step QuantiTect SYBR Green RT PCR kit (QIAGEN)
in a StepOne Real-Time-PCR-Cycler (Applied Biosystems). Cellular RNA was
quantified with specific QuantiTect primers against IFN-b (QT00203763) and
g-actin (QT00996415). For detection of FLUAV segment 7 sequences, reverse
transcription was performed using the QIAGEN QuantiTect Reverse Tran-
scription Kit with the () strand-specific forward (50-GGACTGCAGCGTAGA
CGCTT-30 ) and (+) strand-specific reverse primer (50-CATCCTGTTGTATAT
GAGGCCCAT-30). PCR was performed using QuantiTect SYBR Green PCR.
Values were normalized against g-actin using the DDCT method (Livak and
Schmittgen, 2001). Upregulation of inducible genes is depicted in relation to
nonstimulated, noninfected (mock) cells.
siRNA Knockdown
A549 cells were twice reverse transfected with predesigned siRNAs from
QIAGEN (AllStar Negative Control siRNA and FlexiTube siRNAs against
RIG-I [SI03649037] and MDA5 mRNA [GS23586]). For each siRNA, 25 nM
was diluted in 100 ml DMEM, supplemented with 1 ml Lipofectamine RNAiMAX
Reagent (Invitrogen), and incubated for 15 min at room temperature.
The siRNA transfection mixes were transferred into a 24-well plate, and 1 3
10E5 cells dissolved in 900 ml DMEM 10% FCS were seeded on top. After
48 hr of incubation at 37C with 5% CO2, cells were harvested, and 1 3
10E5 cells were again reverse transfected as described above and incubated
for additional 24 hr at 37C with 5% CO2.
Generation of Knockout Cell Lines
Using GeneJuice reagent (Merck), 2.53 10E4 HEK293T cells were transfected
with plasmids for either a zinc finger nuclease targeting the RIG-I gene or for a
pair of transcription activator-like effectors to nucleases targeting the genes
for MDA5 or MAVS. Two days later, 0.5 cells per well were seeded into six
96-well plates. After 2 weeks, colonies were trypsinized and seeded into two
replica plates. The next day, one of the replicates was lysed (0.2 mg/ml
Proteinase K, 1 mM CaCl2, 3 mM MgCl2, 1 mM EDTA, 1% Triton X-100,
10mMTris [pH 7.5]). Genotypes were obtained by sequencing PCR amplicons
covering the target site of interest (target sequences and primer sequences
available upon request). For each target gene, a clone was selected that had
all alleles disrupted.
VLP System
HEK293 cells were transiently transfected with plasmids in 2 ml GeneJammer
(Agilent) per 1 mg DNA, and medium was changed after 4 hr. VLPs for strain
A/WSN/33 were generated as described (Neumann et al., 2000). HEK293
WT cells were transfected with plasmids for VSV-G oder FLUAV HA (1 mg),
as well as M1 (2 mg), M2 (100 ng), NEP (1 mg), PB2-627E or PB2-627K (1 mg),
PB1 (1 mg), PA (100 ng), NP (1 mg), a firefly luciferase minigenome construct
(1 mg), and a Renilla luciferase construct (pRL-SV40; 75 ng). As negative con-
trol, PB2 was replaced by additional PB1 plasmid. Two days later superna-
tants were collected and treated with 25 U/ml Benzonase (Novagen) for 3 hrst & Microbe 17, 309–319, March 11, 2015 ª2015 Elsevier Inc. 317
at 37C. Cleared cell supernatants were used for VLP infections of HEK293
cells (pretransfected with NP, PA, PB1, and the matching PB2) as described
above. Luciferase activities were measured 48 hr posttransfection (VLP-pro-
ducing cells) or infection (VLP-infected cells). Firefly luciferase activity was
normalized against Renilla activity. Relative polymerase activity is depicted
as fold induction with respect to mock control.
Peptide Inhibitor Treatment
A549 cells seeded at 80% confluency in T25 flasks were washed once with
PBS and infected with A/Thai/KAN-1/04 (moi 1) for 1 hr at 4C. Then, cells
were treated with 10 ng/ml Borna-X-Tat or PB11-15 T6Y-Tat (Wunderlich
et al., 2011) dissolved in medium with 0.2% BSA. At 1 hr posttreatment, cells
were lysed and subjected to the RIG-I conformational switch assay.SUPPLEMENTAL INFORMATION
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